Clinical Trial: The effects of vericiguat and henagliflozin on cardiac function and prognosis in patients with heart failure with reduced ejection fraction (HFrEF) complicated with type 2 diabetes mellitus (T2DM) (China)

Posted On: 2026-09-15

China, Sept. 15 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'The effects of vericiguat and henagliflozin on cardiac function and prognosis in patients with heart failure with reduced ejection fraction (HFrEF) complicated with type 2 diabetes mellitus (T2DM)'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132395

Registration Time: 2026/09/14

Type: Observational study

Primary Sponsor: Affiliated Hospital of Guangdong Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=338600

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: The effects of vericiguat and henagliflozin on cardiac function and prognosis in patients with heart failure with reduced ejection fraction (HFrEF) complicated with type 2 diabetes mellitus (T2DM) (China)